Allison Richards

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma”.

Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2103

N/A

0.571DataRank · unranked

44 citations

John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew Beatty, Jamie Blauvelt +18 more

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007288

N/A

0.542DataRank · unranked

36 citations

Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodríguez-Valentín +20 more

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2768

N/A

0DataRank · unranked

11 citations

Zeynep Eroglu, Islam Eljilany, Jonathan S. Zager, R. Gonzalez, Amod A. Sarnaik +13 more